Peter Johannes Holst

Short presentation

Research theme:

The development of effective vaccines and immunotherapies for chronic infections and cancer

Research approach:

Stipulation of potential effective immune mechanisms for prophylaxis against HIV followed by technology development to stimulate such responses

Technological starting point is typically virus-vectored-vaccines which acts as delivery vehicles for encoded immunogenic payload

Modifications are introduced in either viral vector or the encoded payload. Depending on the obtained effects technologies may then be applied towards HIV models or used against other pathogens and/or cancer.

Current research

•Virus-like-vaccines– Viruses are engineered to encode Virus-Like-particles to stimulate all arms of the adaptive immune system

•Subdominant antigens as vaccine targets for chronic infections – vaccines are designed to stimulate potent immune responses against pathogen fragments that are not naturally immunogenic. Such vaccines achieve synergy with the infection triggered immune response

•Enhanced vaccines inducing cellular immunity to eliminate chronic papillomavirus infection from those already infected

•Vaccines optimized for oligomeric antigen secretion and stimulation of helper T cells to increase immune response breadth toward virus and parasite infections

Fields of interest

•Effective immunity towards chronic infection

•Interplay between vaccines and infection that synergize or worsens protection

•Targeting of cancer with vaccines inducing T cells, antibodies and immune checkpoint blockade

Possible conflicts of interest

Funder and primary owner of InProTher ApS - InProTher pursues vaccines and immunotherapy against HIV, papillomaviruses and cancer

Collaboration with three different biotech companies on cancer immune modulation and

CV

1. Personal data:

Peter Johannes Holst, Tolstojs Alle 14, 2860 Søborg

2. Education:

January 17^th 2009: PhD in health sciences

June 20^th 2005: Master of medicine.

3. Current and most recent positions held:

2011-Present, Associate Professor, Group leader

Department of International Health, Immunology and Microbiology (ISIM),

University of Copenhagen (UCPH).

2008-2011, PostDoc, ISIM, UCPH: Continued studies on virus-delivered T cell adjuvants.

2005-2008, PhD-student, ISIM, UCPH:

Worked on the LCM virus as an HIV model. Supervisor: Professor Jan Pravsgaard Christensen.

2003-2005, Student assistant, ISIM, UCPH:

Worked part-time funded at ISIM, UCPH. Supervisor: Professor Allan Randrup Thomsen.

1998-2003, Student assistant, Department of Pharmacy, UCPH:

Supervisors: Professors Thue W. Schwartz and Mette Marie Rosenkilde.

1999-2000, Research assistant:

Schering Plough Research Institute, New Jersey, USA. Supervisor: Professor Sergio A. Lira.

4. Academic awards and honours:

2001: Young scientist of the year, Faculty of Health Sciences, University of Copenhagen

2007: Winner of Venture Cup, Greater Copenhagen Area

2008: Elite Researcher award, Danish council for independent research

5. Scientific focus areas:
HIV vaccines, vaccine technologies to combat HIV, ways to apply vaccines against HIV, application of vaccine technology against cancer and chronic infections.

6. International relations:

Christian Thirion (CSO, Sirion Biotech, GER), Volker Sandig (CSO ProBioGen, GER), Joko Pamungkas, Huda Hanifah & Diah Iskandriati (Bogor Agricultural University), Ronald S. Veazey, Tulane National Primate Research Center (LA, USA), Georgia Tomaras (Duke University, NC, USA), Ralf Wagner (University of Regensburg, GER), Arya Biragyn (National Institute of Aging, NIH, MD).

7. Supervision (PhD students):
Supervised three PhD-projects including the Lundbeck sponsored “virus-encoded virus-like-particles” project, and two projects sponsored by the faculty of health.

8. Management experience:

6 years of experience as group leader and manager of international projects within HIV, cancer and papillomavirus research. Have also established the biotech company InProTher ApS which recently assembled a consortium (Thirion, Sandig, Wagner above). The consortium received a EUROSTAR grant within papillomavirus research ranked 6 out of 335 in all of the EU.   

Publications:(1-49)(50, 51). *Marks publications as last author.

Reference List

    1.    F. Antenucci et al., Vet. Res. 49, 4 (2018).

    2.    *A. C. Andersson, M. Schwerdtfeger, P. J. Holst, Vaccines 6, (2018).

    3.    *A. C. Andersson, M. Resende, A. Salanti, M. A. Nielsen, P. J. Holst, Vaccine (2017).

    4.    *E. Ragonnaud, A. G. Pedersen, P. J. Holst, Scand. J. Immunol. (2017).

    5.    *E. Ragonnaud et al., J. Immunother. 40, 51 (2017).

    6.    *H. Xu et al., EBioMedicine (2017).

    7.    *C. Fougeroux, P. J. Holst, Int. J. Mol. Sci. 18, (2017).

    8.    F. Antenucci et al., Vet. Res. 48, 74 (2017).

    9.    *E. Ragonnaud, A. M. Andersson, A. E. Pedersen, H. Laursen, P. J. Holst, Vaccine 34, 2147 (2016).

  10.    I. E. Uddback et al., Sci. Rep. 6, 20137 (2016).

  11.    T. M. Clausen et al., Mol. Cancer Res. 14, 1288 (2016).

  12.    L. Nazerai et al., Sci. Rep. 6, 38666 (2016).

  13.    *A. C. Andersson et al., Vaccine 34, 5344 (2016).

  14.    *A. C. Andersson, P. J. Holst, J. Transl. Med. 14, 343 (2016).

  15.    A. K. Niss et al., Blood (2016).

  16.    P. J. Holst, et al., PLoS. ONE. 10, e0117242 (2015).

  17.    A. Salanti et al., Cancer Cell 28, 500 (2015).

  18.    C. Bartholdy et al., Scand. J. Immunol. 79, 395 (2014).

  19.    *B. A. Jensen et al., Mol. Ther. 22, 2107 (2014).

  20.    C. Lee-Chang et al., Blood 124, 1450 (2014).

  21.    J. Pedersen et al., Am. J. Physiol Endocrinol. Metab 304, E60 (2013).

  22.    M. A. Steffensen et al., J. Virol. 87, 6283 (2013).

  23.    *E. Ragonnaud, P. Holst, Ther. Adv. Vaccines. 1, 33 (2013).

  24.    M. A. Steffensen et al., PLoS. ONE. 7, e34884 (2012).

  25.    M. Mikkelsen, P. J. Holst, J. Bukh, A. R. Thomsen, J. P. Christensen, J. Immunol. 186, 2355 (2011).

  26.    P. J. Holst, J. P. Christensen, A. R. Thomsen. Harnessing the Potential of Adenovirus Vectored Vaccines.   169-192. 2011.  In Xu K. ed. Viral Gene Therapy. Rijeka, Croatia, InTech.

  27.    P. L. Danielsen et al., Surgery 150, 897 (2011).

  28.    T. Benned-Jensen et al., J. Biol. Chem. 286, 29292 (2011).

  29.    P. J. Holst, J. P. Christensen, A. R. Thomsen, J. Immunol. 186, 3997 (2011).

  30.    R. Ugleholdt et al., J. Biol. Chem. 286, 44632 (2011).

  31.    P. J. Holst, M. R. Bassi, A. R. Thomsen, J. P. Christensen, Curr. Opin. Mol. Ther. 12, 47 (2010).

  32.    M. R. Sorensen, P. J. Holst, M. A. Steffensen, J. P. Christensen, A. R. Thomsen, Vaccine 28, 6757 (2010).

  33.    J. M. Millward et al., J. Neuroimmunol. 224, 45 (2010).

  34.    P. J. Holst, C. Orskov, A. R. Thomsen, J. P. Christensen, J. Immunol. 184, 4431 (2010).

  35.    M. Grujic, P. J. Holst, J. P. Christensen, A. R. Thomsen, J. Gen. Virol. 90, 414 (2009).

  36.    T. Elvang et al., PLoS. ONE. 4, e5139 (2009).

  37.    M. R. Sorensen, P. J. Holst, H. Pircher, J. P. Christensen, A. R. Thomsen, Eur. J. Immunol. 39, 2725 (2009).

  38.    *M. Hoegh-Petersen, A. R. Thomsen, J. P. Christensen, P. J. Holst, Vaccine 27, 6723 (2009).

  39.    P. J. Holst et al., J. Immunol. 180, 3339 (2008).

  40.    P. J. Holst, J. P. Christensen, A. R. Thomsen, Ugeskr. Laeger 170, 3953 (2008).

  41.    P. J. Holst, C. Bartholdy, A. Stryhn, A. R. Thomsen, J. P. Christensen, J. Gen. Virol. 88, 1708 (2007).

  42.    P. J. Holst, C. Orskov, K. Qvortrup, J. P. Christensen, A. R. Thomsen, J. Virol. 81, 10101 (2007).

  43.    M. M. Rosenkilde et al., J. Biol. Chem. 281, 13199 (2006).

  44.    R. Ugleholdt et al., J. Biol. Chem. 281, 11050 (2006).

  45.    B. Bonnesen et al., Blood 106, 3396 (2005).

  46.    K. A. McLean, P. J. Holst, L. Martini, T. W. Schwartz, M. M. Rosenkilde, Virology 325, 241 (2004).

  47.    M. M. Rosenkilde, K. A. McLean, P. J. Holst, T. W. Schwartz, J. Biol. Chem. 279, 32524 (2004).

  48.    P. J. Holst, M. M. Rosenkilde, Microbes. Infect. 5, 179 (2003).

  49.    P. J. Holst, H. R. Luttichau, T. W. Schwartz, M. M. Rosenkilde, Contrib. Microbiol. 10, 232 (2003).

  50.    P. J. Holst et al., J. Clin. Invest 108, 1789 (2001).

  51.    M. M. Rosenkilde, T. N. Kledal, P. J. Holst, T. W. Schwartz, J. Biol. Chem. 275, 26309 (2000).